Ankylosing spondylitis (AS) is actually a chronic, inflammatory disease that mainly affects the sacroiliac joints and spine in the human. Inflammatory damage in the aforesaid areas normally leads to long-term back pain and exaggerated morning stiffness, which in the long-term results in restriction of spinal mobility and difficulty with activities of daily living [1]. Outside the musculoskeletal system, AS is also found to have extra-articular manifestations, which can include uveitis, psoriasis, and inflammatory bowel disease, all of which are all attributable to the disease burden and patient outcomes [2].
A defining feature of AS is its very strong genetic predisposition. Genetic causes are estimated to be responsible for causing more than 90% of disease susceptibility, the most consistent and strongest being human leukocyte antigen HLA-B27 [3]. Nevertheless, the specific pathogenic mechanism of HLA-B27 continues to be unclear, despite years of study and numerous mechanisms proposed.There are various theories, such as abnormal peptide presentation, endoplasmic reticulum stress caused by misfolding, and molecular mimicry with microbial antigens, but none of them can comprehensively account for the range of clinical manifestations in AS.
2.Current Treatments and Their Limitations
The therapeutic setting for AS has improved significantly over the past two decades. NSAIDs remain the first-line and most effective treatment to alleviate pain and stiffness. Chronic use of NSAIDs does carry meaningful risks such as gastrointestinal bleeding, cardiovascular and renal related complications, thereby creating a clinical dilemma [4].
Unlike rheumatoid arthritis, the therapeutic effect of traditional antirheumatic medications (DMARDs) such as methotrexate or sulfasalazine is very minimal in axial spondyloarthritis and therefore is not indicated in spinal disease, but plays a significant role in the treatment of peripheral arthritis when present [5]. This creates a gap in treatment since many patients with only axial disease are left undertreated when NSAIDs fail or cannot be tolerated.
For these patients, biologics, which are namely tumour necrosis factor (TNF) inhibitor TNF blocker which are cytokine blockers,have revolutionised care. TNF blockers can significantly reduce symptoms and improve quality of life.Certainly, they have their own drawbacks, which themselves are responsible for discontinuation and relapse in most instances; some evidence provides backslide in nearly 79.2% of patients who had previously responded and 84.6% of those in partial remission according to ASAS40 criteria [6]. Also, the high cost of biologic drugs is a concern as far as availability and long-term viability are concerned, particularly in those health systems that are poor. Yet another limitation is that while biologics might control inflammation, they have not demonstrated a good ability to prevent or reverse the structural bone changes that are typical of AS. The inability to inhibit new bone growth, as in syndesmophytes and vertebral fusion, constitutes the biggest unmet need for AS treatment. Unlike other rheumatic diseases, where prevention of erosion and joint damage is the main issue, AS is also uniquely characterised by the phenomenon of overgrowth of bone, which current treatments fail to target well.
3.How Tripterygiumwilfordii Hookcan be used for treating ankylosing spondylitis -
As the period elapsed, the data and findings of the studies have confirmed the limitations in the application of the traditional therapies, and scientists have since then shifted to applying complementary and alternative medicine for new information.
Tripterygium wilfordii Hook (TWH), or "Thunder God Vine," is a Chinese-origin traditional drug plant, whose centuries-long therapeutic application exists for the management of inflammatory and autoimmune disorders (such as rheumatoid arthritis. Its anti-inflammatory, immunomodulatory, and anti-rheumatic activities have been validated by recent pharmacological research [7].
The primary bioactive compound of TWH is triptolide, which has been found to exhibit potential activity in vitro. Bioactive molecules are merely the plant or animal compounds, which can possibly interact with other tissues of living organisms with a health beneficialeffect. For instance, it can be able to suppress the production of collagen, suppress alkaline phosphatase activity, and suppress calcium deposition processes, that have all of which naturally suggest a potential function in modulating pathological new bone formation in AS [7]. This is different from previous AS therapies, which are mainly symptom-based but do not suppress structural lesions adequately.
In addition, clinical medication such as tripterygium glycosides tablets that essentially contain triptolides are a primary bioactive component that have already shown positive responses in AS patients. These are clinical symptomatic remission and suppression of disease-related serum biomarkers, which indicate symptomatic and biological efficacy [8]. Despite all these types of encouraging results, TWH is not without its problems: there have been reports of toxicity and side effects from excessive or prolonged use, so encouraging more total measurement of safety and standardisation of dose.
Early evidence for TWH is encouraging, but still much is not known about how it works. That is where network pharmacology has been such a good ally to us. Unlike the typical pharmacology focus on isolated targets and isolated molecules, network pharmacology provides systems-level information. Network pharmacology integrates computational models, publicly available biological databases, and network analytical programs to screen for bioactive compounds, predict their molecular targets, and explain their activities along interacting biological pathways [9].
This systems biology-inspired strategy is particularly poised to unravel classical Chinese medicine, commonly made up of numerous bioactive ingredients that cooperate synergistically with one another through multiple signal pathways. Under such a scenario, network pharmacology allows investigators to shed light on the "multi-component, multi-target" constellation of herbal preparations and make predictions that would be difficult using traditional reductionist approaches [10].
Applying network pharmacological analysis to TWH in AS can potentially reveal the specific molecular pathways that triptolide and other bioactive molecules act upon. For instance, it can establish whether TWH acts on anti-inflammatory pathways (e.g., NF-κB, JAK-STAT), bone metabolism pathways (e.g., Wnt/β-catenin), or immune regulation pathways (e.g., T-cell differentiation). Such information would not only validate the traditional use of TWH but could also have served as the basis for the development of safer and more targeted derivatives.
Figure 1:Therapeutic mechanisms of triptolide in ankylosing spondylitis. Triptolide, a bioactive compound derived from Tripterygium wilfordii, exerts anti-inflammatory effects by inhibiting T-cell proliferation and suppressing key pro-inflammatory cytokines, including TNF-α and IL-17, thereby alleviating spinal inflammation associated with ankylosing spondylitis.
4. How methazolamidecan be used fortreating ankylosing spondylitis
Methazolamide is an orally effective and tolerable carbonic anhydrase (CA) inhibitor, which possesses some therapeutic potential in ankylosing spondylitis (AS). Earlier research has shown the upregulation of CA1 expression in AS and suggestedthat Methazolamide can regulate disease symptoms [11]. In this study, we aimed to disclose the pathogenic role of CA1 and the pharmacological activity of Methazolamide in AS by using Gene Set Enrichment Analysis (GSEA) integrated with a network pharmacology approach.
Seven of the twelve gene sets related to CA1 were identified as being significantly enriched in the AS group by analysis. CA1 was identified to be a pivotal gene in these sets, particularly for zinc ion binding, arylesterase activity, and one-carbon metabolism [12]. Further functional annotation of target genes—which were calculated from the overlap between AS-associated genes and Methazolamide-specific targets—revealed that the drug is primarily acting through inflammatory pathways. These included regulation of tumour necrosis factor (TNF), interleukin-6 (IL-6), and nitric oxide synthesis [13].From the different studies, it was observed that the therapeutic actions of Methazolamide in AS are mediated by PTGS2, ESR1, GSK3β, JAK2, and NOS2.And mechanisms as follows:
4.1 PTGS2 (COX-2):
Prostaglandin-endoperoxide synthase 2 (PTGS2), or COX-2(NSAID), is an induced enzyme that possesses the ability to induce prostaglandin synthesis during inflammation. Unlike its constitutive isoform COX-1, PTGS2 is rapidly induced by inflammatory and mitogenic stimuli to synthesise more prostaglandins in the inflamed tissues of AS patients [15]. Non-steroidal anti-inflammatory drugs (NSAIDs), which are the first line of treatment of AS, act by inhibiting prostaglandin synthesis [14]. It is thus likely that Methazolamide's interaction with PTGS2 may be held responsible for its analgesic, anti-inflammatory, and antipyretic effects.
4.2 GSK3β (Glycogen Synthase Kinase-3 Beta):
GSK3β is a multifunctional kinase that has been implicated in energy metabolism, inflammation, ER stress, mitochondrial dysfunction, and apoptosis [16]. In AS, miR-29a was inhibited, and its replacement inhibited TNF-α–induced bone loss through GSK3β inhibition and enhancing osteoblast activity via the Wnt/β-catenin signalling pathway [17]. Furthermore, lower levels of GSK3β were observed in ligament tissues of AS patients and during osteogenic differentiation of fibroblasts [18]. Inhibition of GSK3β by methazolamide has therapeutic potential to prevent calcification of ligament and pathological bone loss in AS.
4.3 ESR1 (Estrogen Receptor α):
ESR1 with the ability to encode estrogen receptor alpha, which imparts functions in the case of reproduction, like immune control and bone metabolism [19]. Experimental research stated that administration of estrogen decreases expression of spondyloarthritis in SKG mouse models [20,21]. Clinical trials also suggest estrogen therapy in females and gonadotropin therapy in males with AS can somewhathelp in mitigating symptoms [22]. Methazolamide binding to ESR1, therefore, suggests an estrogen-mediated therapeutic process that could play a role in regulating inflammation and bone density in AS.
4.4 JAK2 (Janus Kinase 2).
JAK2, a non-receptor tyrosine kinase pathway, is the only JAK isoform that can directly be involved in AS [23,24,25]. It contributes to osteoblast differentiation [26] and facilitates IL-23 inflammatory pathways mediated by which are at the core of AS pathophysiology [27]. Notably, JAK inhibitors were found to be highly effective in clinical trials of active AS [28]. Hence, Methazolamide's effect on JAK2 may impart the ability to act via JAK-related immune signalling.
4.5 NOS2 (Inducible Nitric Oxide Synthase).
NOS2 encodesiNOS that can generate nitric oxide independent of calcium signalling [29]. Activation of iNOS was linked with osteoporosis induced by inflammation [30] and has been reported in the gut and immune cells of AS patients [31].Genomewide association study also established NOS2 association with acute anterior uveitis AS patients [32]. Methazolamide's regulation of NOS2 suggests that its clinical effect might be by regulating the production of NO and inhibiting inflammation.
Table 1: Target Genes Regulated by Methazolamide in the Treatment of Ankylosing Spondylitis
|
Target Gene |
Full Name / Protein |
Role in AS Pathophysiology |
|
COX2(PTGS2) |
Prostaglandin-endoperoxide synthase 2 (Cyclooxygenase-2) |
Induced during inflammation; synthesises prostaglandins in inflamed tissues of AS patients; inhibited by NSAIDs (first-line therapy). |
|
GSK3β |
Glycogen Synthase Kinase-3 Beta |
Involved in energy metabolism, ER stress, apoptosis, and bone metabolism; inhibition restores osteoblast activity via the Wnt/β-catenin pathway; low GSK3β is linked to pathological bone formation in AS. |
|
ESR1 |
Estrogen Receptor α |
Regulates immune response and bone metabolism; estrogen shown to decrease spondyloarthritis activity in animal models; some clinical benefit has been seen with hormone therapy in AS patients. |
|
JAK2 |
Janus Kinase 2 |
Key kinase in IL-23/Th17 signalling; contributes to osteoblast differentiation and pro-inflammatory pathways; JAK inhibitors are effective in AS clinical trials |
|
NOS2 (iNOS) |
Inducible Nitric Oxide Synthase |
Produces nitric oxide independent of Ca²?; linked to inflammation-induced osteoporosis; elevated in gut and immune cells of AS |
Figure 2: Molecular mechanisms of methazolamide in ankylosing spondylitis. Methazolamide modulates multiple molecular targets, including CA1, PTGS2, GSK3β, and JAK2, thereby regulating inflammatory responses, bone mineralisation, and immune signalling pathways involved in the treatment of ankylosing spondylitis.
4.6. The therapeutic potential of methazolamide-
Ankylosing spondylitis (AS) is not only defined by the attribute of chronic inflammation but also by the appearance of ectopic new bone, a classic pathological characteristic that ultimately culminates in ankylosis and fusion of spinal joints in severe disease [33].
Carbonic anhydrases (CAs) form a large family of zinc metalloenzymes capable of catalysing the reversible hydration of carbon dioxide. Among all of them, CA1 can play a critical role in bone metabolism. It is involved in the process of calcium carbonate formation [34] and can upset normal bone mineralisation equilibrium by blocking the synthesis of hydroxyapatite through competitive interactions [35,36]. This disruption can cause pathological ossification. In line with this concept, Zheng and colleagues demonstrated that transgenic overexpression of CA1 led to higher scores of arthritis, paw swelling, and longer duration of collagen II-induced arthritis [36].Further studies have also highlighted the significance of clinical relevance of CA1 in AS. Specifically, expression of CA1 was much higher in synovial tissues of AS patients compared with samples obtained from rheumatoid arthritis and osteoarthritis patients [37,38]. These findings effectively indicate that CA1 is involved in disease-specific pathological mechanisms of AS patients.
Other than all of these is therapeutic targeting of CA1, and this has already been shown to have some hopeful attempts. In earlier studies, we demonstrated that Methazolamide, a carbonic anhydrase inhibitor, can be of therapeutic value to AS patients. Treatments with methazolamide brought significant changes in disease activity and function, as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI), with a safety profile. Also, Methazolamide treatment was noted with a more differentiated articular surface of the sacroiliac joints in patients, reflective of blunting of structural evolution [39]. Collectively, they suggested that CA1 is a novel potential pathogenic factor in AS and that Methazolamide is a candidate therapeutic agent that is effective and safe.
By combining bioinformatics tools with prior clinical observations, this study buildson the hypothesis that targeting CA1 may represent a unique therapeutic strategyin AS, bridging the gap between disease pathogenesis and novel pharmacological interventions.
Figure 3: Anti-inflammatory actions of methazolamide in ankylosing spondylitis. Methazolamide targets inflammatory signalling cascades in ankylosing spondylitis by inhibiting carbonic anhydrase activity and suppressing the production of pro-inflammatory cytokines, including IL-17 and TNF-α.
6.HowDanshensu can be used in treating Ankylosing Spondylitis-
Danshensu [3-(3,4-dihydroxy-phenyl) lactic acid] is one of the key bioactive compounds obtained from Salvia miltiorrhiza (Danshen), a Chinese medicinal herb and extensively used in cardiovascular and cerebrovascular therapy [40-41]. Danshensu contains multiple pharmacological activities, such as anti-inflammatory, antioxidant, and anti-apoptotic activities. Danshensu has been used clinically and experimentally to cure cardiovascular diseases such as myocardial ischemia-reperfusion injury, atherosclerosis, and hypertension, and cerebral embolism [42].
Various studies that have been carried out have elucidated its protective mechanism at a molecular level. For example, Danshensu was found to inhibit neuroinflammation by down-regulating hippocampal contents of pro-inflammatory cytokines TNF-α and IL-6 [43]. In myocardial ischemia/reperfusion injury models, Danshensu provided cardioprotection by inhibiting JNK phosphorylation and activation and NF-κB nuclear translocation [44,45] pathways that are also implicated in new bone formation in ankylosing spondylitis (AS).
In addition to cardiovascular protection, Danshensu is also involved in bone physiology. It modulates osteoblast differentiation and activity, indicating possible therapeutic utility in bone disorders. For instance, an H?S-releasing analogue of Danshensu had antioxidant action in a model of H?O?-induced MC3T3-E1 osteoblast damage via suppression of p38 MAPK, ERK1/2, and JNK–MAPK signal pathways [46]. Notably, this is the opposite of the effect of salvianolic acid B, another Salvia miltiorrhiza active compound previously reported to enhance osteogenesis in human mesenchymal stem cells through stimulation of ERK1/2 activation [47]. These results serve to suggest that the varied components of Danshen may have opposing regulatory activities in osteogenic mechanisms. But for such evidence, the application of Danshensu in AS has yet to be investigated. Given its anti-inflammatory and bone-regulating activities, we speculate that Danshensu would inhibit osteoblast and fibroblast pathological ossification in AS. To investigate such a hypothesis, we performed a network pharmacology and experimental verification study. We initially conducted network pharmacology analysis to screen candidate molecular targets of Danshensu. These targets were subsequently assayed for functional enrichment and pathways to identify their relevance in osteoblast differentiation and AS pathology.
Second, we built a disease–drug component–target–pathway interaction network that permitted us to map and prioritize important signaling pathways potentially targeted by Danshensu. This hybrid method permitted us to nominate candidate processes by which Danshensu could modulate inflammation, ossification, and bone remodelling in AS [46]. Third, we determined the efficacy and mechanisms of Danshensu using cell-based experiments in AS-derived osteoblasts and fibroblasts, and provided experimental confirmation of the bioinformatics predictions.
For target prediction, Danshensu structure analysis, SMILES string and InChIKey were retrieved from the PubChem database. The compound was screened in a range of databases such as BATMAN-TCM (threshold: prediction score ≥20, adjusted p < 0.05), TCMSP, SwissTargetPrediction, and PharmMapper to systematically map its putative molecular targets.
Overall, Danshensu is a potential therapeutic candidate for AS according to its reported activities in inflammation, oxidative stress, and bone remodelling. Network pharmacology combined with in vitro validation is an integrated approach that may elucidate its therapeutic targets, and this might facilitate new therapeutic strategies that address both inflammation and pathological ossification in AS.
7.How Xinfeng capsules can be used to treat Ankylosing Spondylitis-
Xinfeng capsules (XFC) are a traditional Chinese medicine preparation made by the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM). In its clinical practice,they can be mainly used to strengthen the spleen, restore or dispel dampness, relieve numbness, and promote circulation in the collaterals [47].Clinical findings have already indicated that XFC is safe and effective in the treatment of ankylosing spondylitis (AS), thus becoming a potential adjunctive treatment option for patients needing it in their long-term therapy [48].
Over the last few years, the growth of medical science in large amounts of data has opened enormous opportunities for studying the clinical efficacy of TCM formulas. Data mining techniques can enable researchers to detect patterns, associations, and clinically significant results that are buried in a vast amount of health data, thus offering evidence that is not always apparent in regular clinical observation [49]. In addition to this, network pharmacology has come to be a valuable tool for the study of intricate treatment systems. By combining data regarding active compounds, molecular targets, signaling pathways, and disease mechanisms, it provides a systems-level picture of how multi-component Chinese medicines could exert therapeutic effects [50].
8.How Cinnamomiramulusis used in treating Ankylosing Spondylitis (AS)
Cinnamomiramulus (also called C. ramulus or Guizhi, GZ) has been used traditionally in the treatment of AS, especially in the southern part of the land like Guangdong, Guangxi, and Yunnan [51]. Doctors comment that treatment with C. ramulus causes remarkable alleviation of pain as well as enhanced joint function in AS patients, with minimal side effects [52,53]. The in vivo and in vitro experimental tests validate the existence of pharmacologically active compounds in C. ramulus that impart anti-inflammatory, antibacterial, antiviral, and antitumor activities, with its anti-inflammatory compounds being especially promising as treatments for AS. However, the individual molecular drivers—i.e., the active compounds, the target proteins, and the complex mechanisms of action—are to be elucidated.
To reveal these, network pharmacology—a cross-disciplinary approach that combines systems biology, computational science, and bioinformatics—is a powerful approach. It enables the detailed mapping of interactions between drugs and disease-related genes, proteins, metabolites, and signalling pathways and facilitates the identification of new therapeutic targets and mechanisms [54].On this platform, network pharmacology was recently used in a study on C. ramulus in AS. By overlaying publicly accessible databases, scientists isolated key active compounds, including 2-methoxycinnamaldehyde, cinnamaldehyde, and 2-hydroxycinnamaldehyde. Overlaying these with what was already known of AS-associated targets determined a list of common proteins. Network analysis placed PTGS2, MMP9, and TLR4 as the highest "hub" targets. Gene Ontology (GO) and KEGG pathway enrichment revealed additional roles in hormonal and peptide response, mitigation of oxidative stress, and inflammation regulation, with major pathways being IL-17, TNF, NF-κB, and Toll-like receptor signalling. Molecular docking also affirmed strong binding affinities among the lead molecules and these major targets. Lastly, immunohistochemical confirmation established elevated PTGS2, MMP9, and TLR4 expression in AS tissue samples in favour of their hypothetical implication.
These investigations laid a sound basis for outlining how C. ramulus may carry out its therapeutic actions in AS and served as a starting point for rational pharmacological investigation and possible clinical application.
Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disease most commonly affecting the spine and sacroiliac joints, resulting in pain, stiffness, and eventually structural fusion. Despite treatment with NSAIDs and biologic therapy against TNF-α and IL-17, a large proportion of patients show an incomplete response or side effects. This imbalance in long-term correct management has stimulated increasing interest in Traditional Chinese Medicine (TCM) and natural products with multitargeted pharmacological mechanisms. New evidence via network pharmacology, molecular docking, and in vitro/in vivo verification has confirmed some candidate targets, including Cinnamomiramulus, Radix Salvia miltiorrhiza (RSM), Danshensu, Methazolamide and Tripterygium wilfordii
Guizhi (Cinnamomiramulus) has been used traditionally in TCM for musculoskeletal disorders. Its anti-inflammatory activity is now supported by pharmacological evidence, primarily by cinnamaldehyde derivatives.
Of the isolated compounds, Danshensu, a bioactive derivative of Salvia miltiorrhiza, has shown cardioprotective, antioxidative, and anti-apoptotic activities. Its potential to inhibit ossification and pathological new bone formation in AS makes it a promising therapeutic compound, but direct evidence in AS is limited and needs to be elucidated.
The inhibitor of carbonic anhydrase (CA), Methazolamide, has also been newly repurposed as a therapeutic agent for AS. Overexpression of CA1 was described in AS synovium, in which it is involved in abnormal mineralisation and ossification of the bone. Network pharmacology and gene set enrichment analysis (GSEA) confirmed that Methazolamide modulates pathways of PTGS2, ESR1, GSK3β, JAK2, NOS2, and CA1 to modulate inflammation, angiogenesis, and bone metabolism.Clinical observations reported suggesting both safety and efficacy.
Tripterygium wilfordii, a widely used TCM drug, has very strong immunomodulatory and anti-inflammatory effects. Its plant extracts, particularly triptolide, inhibit NF-κB activation, repress the release of proinflammatory cytokines, and regulate T-cell-mediated immunity.
In brief, while classical AS treatments remain precious, TCM-derived drugs and agents provide supplementary methods that treat inflammation and ectopic bone formation, the two hallmarks of AS pathology. Their multitarget activity, safety, and integration of traditional perception with modern computer-facilitated pharmacology position them as hopeful applicants to pursue further. However, rigorous in vivo studies and clinical trials have to be conducted to confirm their efficacy and establish standard dosing regimens for clinical application in a safe and controlled way.
I sincerely appreciate Techno India University, West Bengal, for the opportunity and resources to pursue this project. I'm grateful to my biotechnology department and faculty members for their steadfast guidance and support.
This review paper received no external funding.
The author declares no conflicts of interest.
[1] Sieper, J., &Poddubnyy, D. (2017). Axial spondyloarthritis. Lancet (London, England), 390(10089), 73–84. https://doi.org/10.1016/S0140-6736(16)31591-4
[2] de Winter, J. J., van Mens, L. J., van der Heijde, D., Landewé, R., & Baeten, D. L. (2016). Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis research & therapy, 18(1), 196. https://doi.org/10.1186/s13075-016-1093-z
[3] Kanwal, A., & Fazal, S. (2018). Construction and analysis of protein-protein interaction network correlated with ankylosing spondylitis. Gene, 638, 41–51. https://doi.org/10.1016/j.gene.2017.09.049
[4] Kroon, F.P., van der Burg, L.R., Ramiro, S., Landewé, R.B., Buchbinder, R., Falzon, L., & van der Heijde, D.M. (2015). Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). The Cochrane database of systematic reviews, 7, CD010952, .https://doi.org/10.1002/14651858.CD010952.pub2
[5] Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., Geher, P., Hammoudeh, M., Inman, R. D., Jongkees, M., Khan, M. A., Kiltz, U., Kvien, T., Leirisalo-Repo, M., Maksymowych, W. P., Olivieri, I., … van der Heijde, D. (2011). 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the rheumatic diseases, 70(6), 896–904. https://doi.org/10.1136/ard.2011.151027
[6] Haibel, H., Heldmann, F., Braun, J., Listing, J., Kupper, H., &Sieper, J. (2013). Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis and rheumatism, 65(8), 2211–2213. https://doi.org/10.1002/art.38014
[7] Ji, W., Liu, S., Zhao, X., Guo, Y., Xia, S., Lu, Y., Yin, M., & Xu, X. (2017). Triptolide inhibits proliferation, differentiation and induces apoptosis of osteoblastic MC3T3 E1 cells. Molecular medicine reports, 16(5), 7391–7397. https://doi.org/10.3892/mmr.2017.7568
[8] Ji, W., Chen, Y., Zhao, X., Guo, Y., Zhong, L., Li, H., Wang, D., & Song, Y. (2015). Beneficial effects of tripterygium glycosides tablet on biomarkers in patients with ankylosing spondylitis. Molecular medicine reports, 12(1), 684–690. https://doi.org/10.3892/mmr.2015.3448
[9] Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690.https://doi.org/10.1038/nchembio.118
[10] Zhang, J., Huang, Q., Zhao, R., & Ma, Z. (2020). A network pharmacology study on the Tripteryguimwilfordii Hook for treatment of Crohn's disease. BMC complementary medicine and therapies, 20(1), 95. https://doi.org/10.1186/s12906-020-02885-9
[11] Kroon, F.P., van der Burg, L.R., Ramiro, S., Landewé, R.B., Buchbinder, R., Falzon, L., & van der Heijde, D.M. (2015). Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). The Cochrane database of systematic reviews, 7, CD010952 . https://doi.org/10.1002/14651858.CD010952.pub2
[12] Lai, S. W., Kuo, Y. H., & Liao, K. F. (2021). Incidence of inflammatory bowel disease in patients with ankylosing spondylitis. Annals of the rheumatic diseases, 80(9), e144. https://doi.org/10.1136/annrheumdis-2019-216362
[13] Mekkawy KL, Rodriguez HC, Mercadal G, et al. Ankylosing spondylitis in patients undergoing total hip arthroplasty increases the risk of medical and implant-related complications: a case control analysis. HIP International. 2024;34(5):602-607. doi:10.1177/11207000241267706, https://journals.sagepub.com/doi/abs/10.1177/11207000241267706?utm_
[14] Taurog, J. D., Chhabra, A., & Colbert, R. A. (2016). Ankylosing Spondylitis and Axial Spondyloarthritis. The New England journal of medicine, 374(26), 2563–2574. https://doi.org/10.1056/NEJMra1406182
[15] Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23(2), 254–266. https://doi.org/10.1200/JCO.2005.09.112
[16] Wang, H., Kumar, A., Lamont, R. J., & Scott, D. A. (2014). GSK3beta and the control of infectious bacterial diseases. Trends in Microbiology, 22(4), 208–217.https://doi.org/10.1016/j.tim.2014.01.009
[17] Li, C., Zhang, P., & Gu, J. (2015). miR-29a modulates tumor necrosis factor-α-induced osteogenic inhibition by targeting Wnt antagonists. Development, growth & differentiation, 57(3), 264–273. https://doi.org/10.1111/dgd.12207
[18] Tang, S. L., Huang, Q. H., Wu, L. G., Liu, C., & Cai, A. L. (2018). MiR-124 regulates osteoblast differentiation through GSK-3β in ankylosing spondylitis. European review for medical and pharmacological sciences, 22(20), 6616–6624. https://doi.org/10.26355/eurrev_201810_16136
[19] Arnal, J. F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2017). Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to medical implications. Physiological Reviews, 97(3), 1045–1087.https://doi.org/10.1152/physrev.00024.2016
[20] Jeong, H., Bae, E. K., Kim, H., Eun, Y. H., Kim, I. Y., Kim, H., Lee, J., Jeon, C. H., Koh, E. M., & Cha, H. S. (2017). Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model. Arthritis research & therapy, 19(1), 198. https://doi.org/10.1186/s13075-017-1407-9
[21] Wang, L., Wang, B., Gasek, N. S., Zhou, Y., Cohn, R. L., Martin, D. E., Zuo, W., Flynn, W. F., Guo, C., Jellison, E. R., Kim, T., Langhi Prata, L. G. P., Palmer, A. K., Li, M., Inman, C. L., Barber, L. S., Al-Naggar, I. M. A., Zhou, Y., Kuchel, G. A., Meves, A., Tchkonia, T., Kirkland, J. L., Robson, P., & Xu, M. (2022). Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity. Cell Metabolism, 34(1), 75–89.e8.https://doi.org/10.1038/s41598-021-91320-1
[22] Giltay, E. J., van Schaardenburg, D., Gooren, L. J., Popp-Snijders, C., &Dijkmans, B. A. (1999). Androgens and ankylosing spondylitis: a role in the pathogenesis?. Annals of the New York Academy of Sciences, 876, 340–365. https://doi.org/10.1111/j.1749-6632.1999.tb07658.x
[23] Hanson, A., & Brown, M. A. (2017). Genetics and the Causes of Ankylosing Spondylitis. Rheumatic diseases clinics of North America, 43(3), 401–414. https://doi.org/10.1016/j.rdc.2017.04.006
[24] Wei, Y., & Zhang, T. (2024). Janus Kinases and Autoimmunity: Bridging Pathways to Therapy. International Journal of Drug Discovery and Pharmacology.https://doi.org/10.53941/ijddp.2024.100007
[25] Ellinghaus, D., Jostins, L., Spain, S. L., Cortes, A., Bethune, J., Han, B., … Franke, A. (2016). Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics, 48(5), 510–518.https://doi.org/10.1038/ng.3528
[26] Jo, S., Wang, S. E., Lee, Y. L., Kang, S., Lee, B., Han, J., Sung, I. H., Park, Y. S., Bae, S. C., & Kim, T. H. (2018). IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Research & Therapy, 20, 115. https://doi.org/10.1186/s13075-018-1582-3
[27] Vecellio, M., Cohen, C. J., Roberts, A. R., Wordsworth, P. B., & Kenna, T. J. (2019). RUNX3 and T-bet in immunopathogenesis of ankylosing spondylitis: Novel targets for therapy? Frontiers in Immunology, 9, 3132.https://doi.org/10.3389/fimmu.2018.03132
[28] Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., … Smolen, J. S. (2021). Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Annals of the Rheumatic Diseases, 80(1), 71–87. https://doi.org/10.1136/annrheumdis-2020-218398
[29] Wei, Y., & Zhang, T. (2024). Janus Kinases and Autoimmunity: Bridging Pathways to Therapy. International Journal of Drug Discovery and Pharmacology.https://doi.org/10.53941/ijddp.2024.100007
[30] Armour, K.E., van ‘t Hof, R.J., Grabowski, P.S., Reid, D.M., & Ralston, S.H. (1999). Evidence for a Pathogenic Role of Nitric Oxide in Inflammation?Induced Osteoporosis. Journal of Bone and Mineral Research, 14.https://doi.org/10.1359/jbmr.1999.14.12.2137
[31] Lamarque, D., et al. Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis. The Journal of Rheumatology, 30, 2428–2436.
[32] Huang, X. F., et al. (2020). Genome-wide association study of acute anterior uveitis identifies new susceptibility loci. Investigative Ophthalmology & Visual Science, 61(6), 3.https://doi.org/10.1167/iovs.61.6.3
[33] de Vlam, K., Lories, R. J., & Luyten, F. P. (2006). Mechanisms of pathologic new bone formation. Current Rheumatology Reports, 8, 332–337.https://doi.org/10.1007/S11926-006-0061-Z
[34] T Supuran, C. (2021). Novel carbonic anhydrase inhibitors. Future medicinal chemistry.https://doi.org/10.4155/fmc-2021-0222
[35] Mozafari, M., Banijamali, S., Baino, F., Kargozar, S., & Hill, R. G. (2019). Calcium carbonate: Adored and ignored in bioactivity assessment. Acta Biomaterialia, 91, 35–47https://doi.org/10.1016/j.actbio.2019.04.039
[36] Sovová, S., Abalymov, A., Pekar, M., Skirtach, A. G., &Parakhonskiy, B. (2021). Calcium carbonate particles: Synthesis, temperature and time influence on the size, shape, phase, and their impact on cell hydroxyapatite formation. Journal of Materials Chemistry B, 9, 8308–8320.https://doi.org/10.1039/D1TB01533C
[37] Zheng, Y., Wang, L., Zhang, W., Xu, H., & Chang, X. (2012). Transgenic mice overexpressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction. BMC Musculoskeletal Disorders, 13, 256.https://doi.org/10.1186/1471-2474-13-256
[38] Chang, X., et al. (2010). Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis. BMC Musculoskeletal Disorders, 11, 279.https://doi.org/10.1186/1471-2474-11-279
[39] Chang, X., Yan, X., & Zhang, Y. (2011). Treat ankylosing spondylitis with methazolamide. International Journal of Medical Sciences, 8(5), 413–419.https://doi.org/10.7150/ijms.8.413
[40] Zeng, H., Su, S., Xiang, X., Sha, X., Zhu, Z., Wang, Y., et al. (2017). Comparative analysis of the major chemical constituents in Salvia miltiorrhiza roots, stems, leaves and flowers during different growth periods by UPLC-TQ-MS/MS and HPLC-ELSD methods. Molecules, 22(5), 771.https://doi.org/10.3390/molecules22050771
[41] Xie, C., Luo, J., Hu, H., Wang, L., Yu, P., Xu, L., et al. (2021). A novel Danshensu/tetramethylpyrazine derivative attenuates oxidative stress-induced autophagy injury via the AMPK-mTOR-Ulk1 signaling pathway in cardiomyocytes. Experimental and Therapeutic Medicine, 21(2), 118.https://doi.org/10.3892/etm.2020.9550
[42] Zhang, J., Zhang, Q., Liu, G., & Zhang, N. (2019). Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu. European Journal of Pharmacology, 864, 172710.https://doi.org/10.1016/j.ejphar.2019.172710
[43] Zhang, J., Zhang, Q., Liu, G., & Zhang, N. (2019). Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu. European Journal of Pharmacology, 864, 172710.https://doi.org/10.1016/j.ejphar.2019.172710
[44] Meng, Y., Li, W. Z., Shi, Y. W., Zhou, B. F., Ma, R., & Li, W. P. (2016). Danshensu protects against ischemia/reperfusion injury and inhibits the apoptosis of H9c2 cells by reducing calcium overload through the p-JNK-NF-κB-TRPC6 pathway. International Journal of Molecular Medicine, 37(1), 258–266.https://doi.org/10.3892/ijmm.2015.2419
[45] Li, X., Wang, J., Zhan, Z., Li, S., Zheng, Z., Wang, T., et al. (2018). Inflammation intensity-dependent expression of osteoinductiveWnt proteins is critical for ectopic new bone formation in ankylosing spondylitis. Arthritis & Rheumatology, 70(7), 1056–1070.https://doi.org/10.1002/art.40468
[46] Yan, X., Wu, H., Wu, Z., Hua, F., Liang, D., Sun, H., et al. (2017). The new synthetic H?S-releasing SDSS protects MC3T3-E1 osteoblasts against H?O?-induced apoptosis by suppressing oxidative stress, inhibiting MAPKs, and activating the PI3K/Akt pathway. Frontiers in Pharmacology, 8, 7.https://doi.org/10.3389/fphar.2017.00007
[47] Fang, Y. Y., Liu, J., Wan, L., Dong, W. Z., & Wen, J. T. (2019). The mechanism of Xinfeng capsule medicated serum by inhibiting VEGFA/SDF-1/CXCR4 pathway to relieve platelet activation in patients with ankylosing spondylitis. The Journal of Immunology, 35(8), 691–696.https://doi.org/10.19540/j.cnki.cjcmm.20181113.001
[48] Yang, J., Li, Y., Liu, Q., Li, L., Feng, A., Wang, T., Zheng, S., Xu, A., & Lyu, J. (2020). Brief introduction of medical database and data mining technology in the big data era. Journal of Evidence-Based Medicine, 13(1), 57–69.https://doi.org/10.1111/jebm.12373
[49] Yang, J., Li, Y., Liu, Q., Li, L., Feng, A., Wang, T., Zheng, S., Xu, A., & Lyu, J. (2020). Brief introduction of medical database and data mining technology in the big data era. Journal of Evidence-Based Medicine, 13(1), 57–69.https://doi.org/10.1111/jebm.12375
[50] Liu, Z. H., & Sun, X. B. (2012). Network pharmacology: A new opportunity for the modernisation of traditional Chinese medicine. Acta Pharmaceutica Sinica, 47(6), 696–703.https://doi.org/10.1155/2012/149762
[51] Wei, W., Wu, S., Zhou, C., Chen, T., Zhu, J., Feng, S., Zhan, X., & Liu, C. (2023). Network pharmacology combined with molecular docking and experimental validation to explore the potential mechanism of Cinnamomiramulus against ankylosing spondylitis. Annals of Medicine, 55(2), Article 2287193.https://doi.org/10.1080/07853890.2023.2287193
[52] Liu, J., Zhang, Q., Li, R. L., & et al. (2020). The traditional uses, phytochemistry, pharmacology and toxicology of Cinnamomiramulus:A review. Journal of Pharmacy and Pharmacology, 72(3), 319-342.https://doi.org/10.1111/jphp.13189
[53] Liu, J., Zhang, Q., Li, R. L., & et al. (2020). The traditional uses, phytochemistry, pharmacology and toxicology of Cinnamomiramulus:A review. Journal of Pharmacy and Pharmacology, 72(3), 319-342.https://doi.org/10.1111/jphp.13189
[54] Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682690. https://doi.org/10.1038/nchembio.118
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications